Bitopertin is primarily investigated for its potential therapeutic applications in psychiatric and neurological disorders. It functions as a glycine reuptake inhibitor, targeting the glycine transporter type 1 (GlyT1), which plays a role in modulating NMDA receptor activity in the brain. This mechanism makes it a candidate for treating conditions like schizophrenia, particularly in addressing negative symptoms such as social withdrawal and cognitive deficits. Clinical trials have explored its efficacy in improving these symptoms, though results have been mixed. Additionally, research has examined its potential in treating other conditions involving glutamatergic dysfunction, such as depression and anxiety disorders. Its application remains under study, with ongoing efforts to better understand its therapeutic potential and optimize its use in clinical settings.